Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2025)

Aclaris Therapeutics has reported EBITDA Margin over the past 9 years, most recently at 1527.57% for Q4 2025.

  • Quarterly results put EBITDA Margin at 1527.57% for Q4 2025, down 47576.0% from a year ago — trailing twelve months through Dec 2025 was 823.03% (down 11867.0% YoY), and the annual figure for FY2025 was 823.03%, down 11863.0%.
  • EBITDA Margin for Q4 2025 was 1527.57% at Aclaris Therapeutics, down from 439.5% in the prior quarter.
  • Over the last five years, EBITDA Margin for ACRS hit a ceiling of 2.66% in Q4 2023 and a floor of 1622.58% in Q2 2023.
  • Median EBITDA Margin over the past 5 years was 1005.84% (2021), compared with a mean of 889.3%.
  • Peak annual rise in EBITDA Margin hit 122182bps in 2024, while the deepest fall reached -104914bps in 2024.
  • Aclaris Therapeutics' EBITDA Margin stood at 1533.98% in 2021, then surged by 77bps to 349.12% in 2022, then soared by 99bps to 2.66% in 2023, then crashed by -39388bps to 1051.81% in 2024, then tumbled by -45bps to 1527.57% in 2025.
  • The last three reported values for EBITDA Margin were 1527.57% (Q4 2025), 439.5% (Q3 2025), and 865.56% (Q2 2025) per Business Quant data.